Germline polymorphisms as modulators of cancer phenotypes

BMC Medicine

Volumn 6, Issue , 2008, Pages

  Tan, Patrick ^a,b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLUCURONOSYLTRANSFERASE 1A1; PROSTATE STEM CELL ANTIGEN; PROTEIN MDM2; PROTEIN P53; TUMOR PROTEIN;

CANCER RELAPSE; CARCINOGENESIS; COHORT ANALYSIS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; GERM LINE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; NOTE; PHENOTYPE; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR CELL; ANIMAL; GENETIC POLYMORPHISM; GENETICS; MUTATION; NEOPLASM; PATHOPHYSIOLOGY;

ANIMALS; GERM-LINE MUTATION; HUMANS; NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 52449088067     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-6-27     Document Type: Note

References (18)

1. McCarthy MI Abecasis GR Cardon LR Goldstein DB Little J Ioannidis JPA Hirschhorn JN: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008, 9:356-369. 10.1038/nrg2344 18398418
2. The International HapMap Consortium: A haplotype map of the human genome. Nature 2005, 437:1299-1320. 1880871 16255080 10.1038/nature04226
3. Easton DF Pooley KA Dunning AM Pharoah PDP Thompson D Ballinger DG Struewing JP Morrison J Field H Luben R Wareham N Ahmed S Healey CS Bowman R The SEARCH collaborators Meyer KB Haiman CA Kolonel LK Henderson BE Marchand LL Brennan P Sangrajrang S Gaborieau V Odefrey F Shen CY Wu PE Wang HC Eccles D Evans DG Peto J Fletcher O Johnson N Seal S Stratton MR Rahman N Chenevix-Trench G Bojesen SE Nordestgaard BG Axelsson CK Garcia-Closas M Brinton L Chanock S Lissowska J Peplonska B Nevanlinna H Fagerholm R Eerola H Kang D Yoo KY Noh DY Ahn SH Hunter DJ Hankinson SE Cox DG Hall P Wedren S Liu J Low YL Bogdanova N Schürmann P Dörk T Rob A Tollenaar EM Jacobi CE Devilee P Klijn JGM Sigurdson AJ Doody MM Alexander BH Zhang J Cox A Brock IW MacPherson G Reed MWR Couch FJ Goode EL Olson JE Meijers-Heijboer H Ouweland AVD Uitterlinden A Rivadeneira F Milne RL Ribas G Gonzalez-Neira A Benitez J Hopper JL McCredie M Southey M Giles GG Schroen C Justenhoven C Brauch H Hamann U Ko YD Spurdle AB Beesley J Chen X kConFab and AOCS Management Group Mannermaa A Kosma VM Kataja V et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093. 10.1038/nature05887 17529967
4. Hung: RJ McKay JD Gaborieau V Boffettal P Hashibe M Zaridze D Mukeria A Szeszenia-Dabrowska N Lissowska J Rudnai P Fabianova E Mates D Bencko V Foretova L Janout V Chen C Goodman G Field JK Liloglou T Xinarianos G Cassidy A McLaughlin J Liu G Narod S Krokan HE Skorpen F Elvestad MB Hveem K Vatten L Linseisen J Clavel-Chapelon F Vineis P Bueno-de-Mesquita HB Lund E Martinez C Bingham S Rasmuson T Hainaut P Riboli E Ahrens W Benhamou S Lagiou P Trichopoulos D Holcátová I Merletti F Kjaerheim K Agudo A Macfarlane G Talamini R Simonato L Lowry R Conway DI Znaor A Healy C Zelenika D Boland A Delepine M Foglio M Lechner D Matsuda F Blanche H Gut I Heath S Lathrop M Brennan P: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008m 452:633-637. 10.1038/nature06885 18385738
5. Study Group of Millennium Genome Project for Cancer Sakamoto H Yoshimura K Saeki N Katai H Shimoda T Matsuno Y Saito D Sugimura H Tanioka F Kato S Matsukura N Matsuda N Nakamura T Hyodo I Nishina T Yasui W Hirose H Hayashi M Toshiro E Ohnami S Sekine A Sato Y Totsuka H Ando M Takemura R Takahashi Y Ohdaira M Aoki K Honmyo I Chiku S Aoyagi K Sasaki H Ohnami S Yanagihara K Yoon KA Kook MC Lee YS Park SR Kim CG Choi IJ Yoshida T Nakamura Y Hirohashi S: Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008, 40:730-740. 10.1038/ng.152 18488030
6. Van Ness B Ramos C Haznadar M Hoering A Haessler J Crowley J Jacobus S Oken M Rajkumar V Greipp P Barlogie B Durie B Katz M Atluri G Fang G Gupta R Steinbach M Kumar V Mushlin R Johnson D Morgan G: Genomic variation in myeloma: Design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression free survival. BMC Med 2008, 6:26. 18778477 10.1186/1741-7015-6-26
7. Hanahan D Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9 10647931
8. Vijver Van de M He YD Van't Veer LJ Dai H Hart AAM Voskuil DW Schreiber GJ Peterse JL Roberts C Marton MJ Parrish M Atsma D Witteveen A Glas A Delahaye L Velde van der T Bartelink H Rodenhuis S Rutgers ET Friend SH Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967 12490681
9. Lynch TJ Bell DW Sordella R Gurubhagavatula S Okimoto RA Brannigan BW Harris PL Haserlat SM Supko JG Haluska FG Louis DN Christiani DC Settleman J Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitini. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938 15118073
10. Paez JG Jänne PA Lee JC Tracy S Greulich H Gabriel S Herman P Kaye FJ Lindeman N Boggon TJ Naoki K Sasaki H Fujii Y Eck MJ Sellers WR Johnson BE Meyerson M: EGCR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314 15118125
11. Innocenti F Undevia SD Iyer L Chen PX Das S Kocherginsky M Karrison T Janisch L Ramírez J Rudin CM Vokes EE Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004, 22:1382-1388. 10.1200/ JCO.2004.07.173 15007088
12. Hunter K Welch DR Liu ET: Genetic background is an important determinant of metastatic potential. Nat Genet 2003, 34:23-24. 10.1038/ng0503-23b 12721549
13. Ohmiya N Taguchi A Mabuchi N Itoh A Hirooka Y Niwa Y Goto H: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006, 24:4434-4440. 10.1200/JCO.2005.04.1459 16983111
14. Tricot G Spencer T Spoon D Sawyer J Desikan R Fassas A Badros A Zangari M Munshi N Anaissie E Toor A Barlogie B: Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2001, 116:211-217. 10.1046/ j.1365-2141.2002.03231.x
15. Bank on a Cure http://myeloma.org/main.jsp?type=article&tab_id= 1&menu_id=0&id=670
16. Carrasco DR Tonon G Huang Y Zhang Y Sinha R Feng B Stewart JP Zhan F Khatry D Protopopova M Protopopov A Sukhdeo K Hanamura I Stephens O Barlogie B Anderson KC Chin L Shaughnessy JD Jr Brennan C DePinho RA: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006, 9:313-325. 10.1016/j.ccr.2006.03.019 16616336
17. Zhan F Huang Y Colla S Stewart JP Hanamura I Gupta S Epstein J Yaccoby S Sawyer J Burington B Anaissie E Hollmig K Pineda-Roman M Tricot G van Rhee F Walker R Zangari M Crowley J Barlogie B Shaughnessy JD Jr: The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028. 1895543 16728703 10.1182/blood-2005-11-013458
18. Tan BK Tan LK Yu K Tan PH Lee M Sii LH Wong CY Ho GH Yeo AW Chow PK Koong HN Yong WS Lim DT Ooi LL Soo KC Tan P: Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res 2008, 14:461-469. 10.1158/1078-0432.CCR-07-0999 18223220